Filing Flows

Filing Flows › Immunome (IMNM) › Next earnings date

Immunome (IMNM) earnings on Nov 10, 2026: what to expect

Immunome (IMNM) is expected to report earnings on Nov 10, 2026 (estimated), in 2 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.60 (−$0.71 to −$0.41, 15 estimates) on revenue of $133K, against −$0.65 a year ago. It beat the EPS estimate in 0% of the quarters on record; Filing Flows' model gives it a 43% chance of beating next time.

Report dateNov 10, 2026 (estimated)
Days to go2
EPS estimate−$0.60
Revenue estimate$133K
Beat rate0%

What to watch

Last quarter (Q2 2025) the lines that make up revenue grew like this; the report shows whether the trend holds:

Immunome: revenue lines, growth year over year, Q2 2025Immunome: revenue lines, growth year over year, Q2 2025Revenue+70%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.65, against the analysts' −$0.60.

The last report

Immunome reported revenue of $4.0M for the second quarter 2025 (+70% Y/Y), net loss $43.4M. How it makes money → · Every quarter →

Immunome: EPS against the estimate, last 3 reportsImmunome: EPS against the estimate, last 3 reportsEstimateReported−$0.54−$0.65Nov 25−$0.57−$0.76Mar 26−$0.50−$0.65Aug 26
Latest (Aug 26): Estimate −$0.50, Reported −$0.65.

Immunome's latest quarter

Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.

Questions

When does IMNM report earnings?

Immunome is expected to report on Nov 10, 2026 (estimated).

What are analysts expecting from Immunome?

EPS of −$0.60 and revenue of $133K for the quarter.

Does Immunome usually beat earnings?

It beat the consensus EPS estimate in 0% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.